Sygnature Discovery is a leading provider of integrated drug discovery services, offering a comprehensive range of solutions to the pharmaceutical and biotechnology industries. Founded in 2010, the company has established itself as a trusted partner for organizations seeking to advance their drug discovery programs. With a strong focus on innovation and excellence, Sygnature Discovery combines scientific expertise with cutting-edge technology to deliver high-quality results.
The company operates from its headquarters in Nottingham, United Kingdom, and has built a reputation for its collaborative approach, working closely with clients to understand their specific needs and challenges. Sygnature Discovery’s team of experienced scientists and researchers are dedicated to providing tailored solutions that accelerate the drug discovery process, from early-stage research to preclinical development.
Sygnature Discovery offers a wide range of services, including medicinal chemistry, biology, DMPK (drug metabolism and pharmacokinetics), and in vitro and in vivo pharmacology. By leveraging its multidisciplinary expertise, the company is able to support clients at every stage of the drug discovery pipeline, ensuring that projects are delivered on time and within budget.
With a commitment to quality and a focus on delivering value, Sygnature Discovery continues to expand its capabilities and enhance its service offerings. The company is dedicated to fostering long-term partnerships with its clients, driving innovation in drug discovery, and ultimately contributing to the development of new therapies that improve patient outcomes.